Note: Ingredients listed on restricted chemical lists
EC/CAS
94-13-3
Name of the chemical
Propylparaben; propyl 4-hydroxybenzoate
Concentration
N/A
EC/CAS
99-76-3
Name of the chemical
4-hydroxybenzoic acid, methyl ester
Concentration
N/A
EC/CAS
7732-18-5
Name of the chemical
Water, distilled, conductivity or of similar purity H2O
Concentration
N/A
General Information
Version
02/19/2024
Revision date
2024-02-19
Product name
Fluphenazine Hydrochloride Injection, USP
Product name
Fluphenazine Hydrochloride Injection, USP
Identification on the label/Trade name
Fluphenazine Hydrochloride Injection, USP | Manufacturer Fresenius Kabi USA LLC
Manufacturer Name
Fresenius Kabi USA, LLC
Icons in SDS
Company Information
company name
Fresenius Kabi USA, LLC
GHS Information
Signal word
DANGER
Hazard Codes
Hazard statements (CLP)
H317, H334
Hazard statements
Code
Statements
H317
May cause an allergic skin reaction
Section 2
Signal word
DANGER. GHS Class Respiratory sensitisation. category 1. Skin Sensitization. category 1.
Hazard statements
May cause allergy or asthma symptoms or breathing difficulties if inhaled. May cause an allergic skin reaction.
Precautionary statements
Avoid breathing dust/fume/gas/mist/vapours/spray. Contaminated work clothing should not be allowed out of the workplace. Wear protective gloves/protective clothing/eye protection/face protection. In case of inadequate ventilation wear respiratory protection. IF ON SKIN: Wash with plenty of water. IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing. Specific treatment (see ... on this label). If skin irritation or rash occurs: Get medical advice/attention. If experiencing respiratory symptoms: Call a POISON CENTER or doctor/physician. Take off contaminated clothing and wash it before reuse. Dispose of contents/container in accordance with Local, State, Federal and Provincial regulations. Emergency Overview This product is intended for therapeutic use only when prescribed by a physician. Potential adverse reactions from prescribed doses and overdoses are described in the package insert.
Principle Routes of Exposure
Inhalation Ingestion Eye contact Skin Absorption. Injection.
Potential health effects
Eye Contact with eyes may cause irritation. Skin May cause skin irritation. Inhalation May cause irritation of respiratory tract. Ingestion May cause irritation. Signs/Symptoms Adverse reactions from therapeutic doses include: pseudoparkinsonism, dystonia, dyskinesia, akathisia, oculogyric crises, opisthotonos, hyperflexia, muscle rigidity, neuroleptic malignant syndrome, leukocytosis, elevated CPK, liver function abnormalities, acute renal failure, drowsiness, lethargy, blurred vision, glaucoma, hypertension and fluctuations in blood pressure, nausea, loss of appetite, salivation, polyuria, perspiration, dry mouth, headache, weight change, peripheral edema, skin disorders (itching, erythema, urticaria, photosensitivity), and liver damage manifested by cholestatic jaundice. Occupational exposure has not been fully investigated. Aggravation of Pre-Existing Pre-existing skin and respiratory conditions, as well as cholestatic jaundice, dermatoses, or other Conditions allergic reactions to phenothiazine derivatives.
